NeuroNascent: Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease

(marketscreener.com) CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for its proprietary oral therapeutic, NNI-362, to proceed into Phase 1...http://www.marketscreener.com/news/Neuronascent-Announces-FDA-Clearance-of-IND-Application-for-NNI-362-an-Aging-Therapy-to-Treat-Alzhei--28549593/?utm_medium=RSS&utm_content=20190507